A new clinical study is recruiting participants to evaluate the performance of cutting-edge medical device technology in assessing skin microcirculation for patients suffering from lower limb atherosclerosis. Coordinated by ODI Medical AS, this research focuses on leveraging their proprietary ODI-Tech medical device.
In this article:
- What changed?
- What does the study focus on?
- Why is this important for clinicians and regulators?
- Frequently Asked Questions (FAQs)
- Conclusion
- Disclaimer
- Full announcement
What changed?
The clinical trial officially began recruitment as of January 12, 2026. Its primary aim is to assess skin microcirculation in patients diagnosed with atherosclerosis in the arteries of the extremities. This disorder, characterized by reduced blood flow, is associated with significant clinical risks. The study utilizes ODI Medical AS’s innovative device called ODI-Tech, which seeks to deliver safer and more accurate diagnostic insights.
What does the study focus on?
Atherosclerosis in the arteries of the extremities remains a consistent challenge for healthcare providers and researchers alike. This study targets the following key areas:
- Diagnosing and understanding the impact of atherosclerosis on skin microcirculation in the lower limbs.
- Testing ODI-Tech’s reliability and efficiency in measuring vital parameters non-invasively.
- Providing clinical evidence to support device safety and performance in line with regulatory expectations.
The ODI-Tech examination procedure is included as the single intervention under investigation, aiming to enhance patient outcomes through accurate detection and monitoring.
Why is this important for clinicians and regulators?
Identifying effective diagnostic tools for vascular conditions is critical for timely intervention and lowering risks of complications such as ischemic ulcers or amputations. Regulators and governing bodies require performance data to assess device benefits against risks. Trials like this one address these needs by supplying real-world evidence under controlled conditions.
Moreover, the findings could pave the way for advancements in European and international medical device compliance regulations. ODI Medical’s efforts align with guidelines under MDR (Medical Devices Regulation) Annex XIV, showcasing their commitment to demonstrating device performance and safety.
Frequently Asked Questions (FAQs)
1. What is ODI-Tech?
The ODI-Tech device is designed to assess the microcirculation of the skin, which can help identify vascular issues.
2. Who is sponsoring this study?
ODI Medical AS is sponsoring and overseeing this clinical trial.
3. What conditions are being studied?
This trial targets atherosclerosis in the arteries of the extremities, which affects blood flow in lower limbs.
4. How can I learn more?
Details are available on ClinicalTrials.gov. Refer to the link provided in the announcement below.
Conclusion
This research marks a key step forward in validating innovative diagnostic solutions for atherosclerosis patients. Clinical, regulatory, and quality teams should closely monitor the outcomes for insights into patient care impacts and device compliance pathways.
Disclaimer
This article is for informational purposes only and does not constitute legal advice. All medical device claims are based on available source data.
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07312383?term=medical+device